Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126162851 | 12616285 | 1 | I | 20160722 | 20160802 | 20160802 | EXP | TR-TEVA-681521ISR | TEVA | BESEN AA, KOSE F, MERTSOYLU H, DISEL U, OZYILKAN O. FEBRILE NEUTROPENIA DUE TO H1N1 INFECTION: RARE ENTITY. JOURNAL OF ONCOLOGICAL SCIENCE.2016; 1(1): 8-9. | 47.00 | YR | M | Y | 0.00000 | 20160802 | MD | TR | TR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126162851 | 12616285 | 1 | PS | METHOTREXATE. | METHOTREXATE | 1 | HIGH DOSE | U | 81099 | ||||||||||
| 126162851 | 12616285 | 2 | SS | VINCRISTINE | VINCRISTINE | 1 | U | 75493 | |||||||||||
| 126162851 | 12616285 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | U | 0 | |||||||||||
| 126162851 | 12616285 | 4 | SS | CYTARABINE. | CYTARABINE | 1 | HIGH DOSE | U | 0 | ||||||||||
| 126162851 | 12616285 | 5 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | U | 0 | |||||||||||
| 126162851 | 12616285 | 6 | SS | RITUXIMAB | RITUXIMAB | 1 | U | 0 | |||||||||||
| 126162851 | 12616285 | 7 | SS | DOXORUBICIN | DOXORUBICIN | 1 | U | 63097 | |||||||||||
| 126162851 | 12616285 | 8 | C | FLUCONAZOLE. | FLUCONAZOLE | 1 | 0 | ||||||||||||
| 126162851 | 12616285 | 9 | C | VALACICLOVIR | VALACYCLOVIR HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126162851 | 12616285 | 10 | C | GRANULOCYTE COLONY STIMULATING FACTOR | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | 0 | ||||||||||||
| 126162851 | 12616285 | 11 | C | LEVOFLOXACIN. | LEVOFLOXACIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126162851 | 12616285 | 1 | Mantle cell lymphoma |
| 126162851 | 12616285 | 2 | Mantle cell lymphoma |
| 126162851 | 12616285 | 3 | Mantle cell lymphoma |
| 126162851 | 12616285 | 4 | Mantle cell lymphoma |
| 126162851 | 12616285 | 5 | Mantle cell lymphoma |
| 126162851 | 12616285 | 6 | Mantle cell lymphoma |
| 126162851 | 12616285 | 7 | Mantle cell lymphoma |
| 126162851 | 12616285 | 8 | Infection prophylaxis |
| 126162851 | 12616285 | 9 | Infection prophylaxis |
| 126162851 | 12616285 | 11 | Infection prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126162851 | 12616285 | HO |
| 126162851 | 12616285 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126162851 | 12616285 | H1N1 influenza | |
| 126162851 | 12616285 | Influenza | |
| 126162851 | 12616285 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |